Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of S086 plus amlodipine in essential hypertension uncontrolled on S086 monotherapy
ChiCTR2500111337Phase 3Completed
- Sponsor
- Peking University First Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing S086 plus amlodipine with S086 alone (2 arms). Primary endpoint: Change in mean sitting systolic blood pressure (msSBP) at week 12 versus baseline. Started Oct 2025; status: completed.
02
Drugs
S086amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2500111337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111337.